EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Theranostic nanoplatform for high‐performance dual‐modal magnetic resonance imaging‐guided therapy of orthotopic hepatocellular carcinoma

Jiayin Lin, Wenbo Chen, Xiuqi Hou, Kai Wang, Fan Liu, Ruling Zhang, Zhong Cao, Jian Zheng

BMEMat · 2026-06 · 4 (2)

DOI: 10.1002/bmm2.70061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMEMat, online erschienen am 18.01.2026. Verfasst von Jiayin Lin und 7 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Magnetic resonance imaging (MRI) techniques are essential for the diagnosis of hepatocellular carcinoma (HCC) and the development of precise treatment strategies. Multifunctional diagnostic agents integrating MRI capabilities have attracted considerable interest in precision oncology. In this study, a biomimetic nanoparticle (HAMM NPs) is engineered through the synthesis of Mn 2+ ‐doped mesoporous polydopamine (Mn‐MPDA) as a drug carrier, followed by loading the hydrophilic sonosensitizer artesunate (ART) and coating with Hepa1‐6 cell membranes. The resulting Hepa1‐6@ART@Mn‐MPDA nanoparticles (HAMM NPs) exhibit enhanced tumor accumulation owing to the homologous targeting capability conferred by the Hepa1‐6 cell membrane. Under the acidic conditions of the tumor microenvironment, HAMM NPs undergo pH‐triggered release of Mn 2+ and ART. HAMM NPs exhibit excellent T 1 /T 2 dual‐modality MRI capability enabling precise liver cancer imaging and MRI‐guided sonodynamic therapy (SDT). Upon ultrasound activation, ART generates cytotoxic reactive oxygen species in an oxygen‐independent manner, which synergizes with Mn 2+ ‐mediated chemodynamic therapy via Fenton‐like reactions. In both subcutaneous and orthotopic HCC models, HAMM NPs effectively inhibit tumor growth. This strategy overcomes the limitations of conventional SDT in hypoxic tumors, offering a promising approach for imaging‐guided combination therapy against deep‐seated tumors.

Zitieren

APA

Lin, J., Chen, W., Hou, X., Wang, K., Liu, F., Zhang, R., Cao, Z., & Zheng, J. (2026). Theranostic nanoplatform for high‐performance dual‐modal magnetic resonance imaging‐guided therapy of orthotopic hepatocellular carcinoma. BMEMat, 4(2). https://doi.org/10.1002/bmm2.70061

Vancouver

Lin J, Chen W, Hou X, Wang K, Liu F, Zhang R, et al. Theranostic nanoplatform for high‐performance dual‐modal magnetic resonance imaging‐guided therapy of orthotopic hepatocellular carcinoma. BMEMat. 2026;4(2). doi:10.1002/bmm2.70061

BibTeX
@article{Lin2026,
  author = {Lin, Jiayin and Chen, Wenbo and Hou, Xiuqi and Wang, Kai and Liu, Fan and Zhang, Ruling and Cao, Zhong and Zheng, Jian},
  title = {Theranostic nanoplatform for high‐performance dual‐modal magnetic resonance imaging‐guided therapy of orthotopic hepatocellular carcinoma},
  journal = {BMEMat},
  year = {2026},
  volume = {4},
  number = {2},
  doi = {10.1002/bmm2.70061}
}
Kostenlos starten →